James H. Ellis

James H. Ellis

Auto-generated profile, based on publicly available information

James H. Ellis

Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Radiology
Verified
Journal Article
Closed access
SSStuart G. Silverman
Stuart G. Silverman
IPIvan Pedrosa
Ivan Pedrosa
JEJames H. Ellis
James H. Ellis
NHNicole M. Hindman
Nicole M. Hindman
NSNicola Schieda
Nicola Schieda
MDMatthew S. Davenport
Matthew S. Davenport
It is hoped that this review of the current Bosniak classification and the proposed update will enhance the classification’s clarity and specificity, be useful in clinical practice, serve as substr... Cystic renal cell carcinoma (RCC) is almost certainly overdiagnosed and overtreated. Efforts to diagnose and treat RCC at a curable stage result in many benign neoplasms and indolent cancers being ...

1 November 2018 in Radiology
Verified
Journal Article
Closed access
RMRobert J. McDonald
Robert J. McDonald
DLDeborah Levine
Deborah Levine
JWJeffrey Weinreb
Jeffrey Weinreb
EKEmanuel Kanal
Emanuel Kanal
MDMatthew S. Davenport
Matthew S. Davenport
HKHerbert Y. Kressel
Herbert Y. Kressel
Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research. ©RSNA, 2018 Online supplemental material is available for this article .

1 September 2009 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
JEJames H. Ellis
James H. Ellis
RCRichard H. Cohan
Richard H. Cohan

1 March 2017 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
MDMatthew S. Davenport
Matthew S. Davenport
KPKushal R. Parikh
Kushal R. Parikh
WMWilliam W. Mayo-Smith
William W. Mayo-Smith
GIGary M. Israel
Gary M. Israel
RBRichard K.J. Brown
Richard K.J. Brown
JEJames H. Ellis
James H. Ellis

1 December 2016 in Urology
Verified
Journal Article
Closed access
SASapan N. Ambani
Sapan N. Ambani
TMTodd M. Morgan
Todd M. Morgan
JMJeffrey S. Montgomery
Jeffrey S. Montgomery
AGAdam J. Gadzinski
Adam J. Gadzinski
BJBruce L. Jacobs
Bruce L. Jacobs
JWJ. Stuart Wolf
J. Stuart Wolf

8 March 2011 in Cancer
Verified
Journal Article
Open access
PDF file
KEKhaled M. Elsayes
Khaled M. Elsayes
JEJames H. Ellis
James H. Ellis
TETohamy Elkhouly
Tohamy Elkhouly
JRJustin M. Ream
Justin M. Ream
MBMichyla Bowerson
Michyla Bowerson
ECElaine M. Caoili
Elaine M. Caoili
BACKGROUND: The diagnostic yield was evaluated of percutaneous image‐guided tissue biopsy of hepatic lesions identified on computed tomography performed for staging of a primary malignancy, and it was determined how often the biopsy result was unexpectedly negative, benign, or secondary to a second unknown malignancy.METHODS: In a retrospective investigation from 1998 through 2008, 580 patients with primary malignancies had indeterminate focal hepatic lesions and underwent percutaneous image‐guided biopsy; 369 patients had lesions in their liver at first cross‐sectional imaging, performed for staging; 211 patients had a negative liver imaging study, followed by the subsequent appearance of at least 1 indeterminate suspicious lesion. The results of percutaneous image‐guided tissue biopsies were compared with the histology of the primary malignancy.RESULTS: Liver biopsies were performed in 580 patients (288 men and 292 women; age, 25‐92 years; mean age, 61 years). The most common primary malignancies were pancreatic (n = 96), breast (n = 85), melanoma (n = 57), esophageal (n = 51), lung (n = 47), colorectal (n = 37), and urothelial tumors (n = 26). Biopsy results were positive for malignancy in 528 (91%) cases. Among the positive biopsies, 29 (5%) cases had pathology results different from the primary tumor. Of the 52 biopsies negative for malignancy, 20 yielded a specific benign diagnosis, and 32 were nondiagnostic.CONCLUSIONS: If all liver lesions had been assumed to be metastases, as expected secondary to the known primary tumor, then the true or presumed alternate diagnosis would have been missed in 60 (10.3%) of the 580 cases. The authors did not attempt to determine whether actual clinical management changed based on these 60 liver biopsy results, so this number is an upper bound on management change. On the basis of these results, and given the minimal complication rate of liver biopsy, the authors suggest that liver biopsy should still be performed in the types of cases studied here, despite the finding that the vast majority of biopsies produced the expected result and presumably did not change patient management. Cancer 2011;. © 2011 American Cancer Society.